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Organ motion has been previously described using a probability distribution function that depends
solely upon the amplitude of motion and the degree of asymmetry in the breathing cycle, and that
function has been used with patient specific parameters to correct static dose distributions for
patient breathing using a dose convolution method. In this study, the consequences of errors in the
selection of those two parameters were evaluated. Patients previously treated using a focal liver
dose escalation protocol were selected with tumors located in the superior or inferior portion of the
liver. For a fixed degree of asymmetry ~amplitude!, the amplitude ~asymmetry! of motion was
varied about its nominal value and the consequences of organ motion on the dose distribution and
the ~potentially new! prescription dose were evaluated. These comparisons show that small ~63
mm! variations of the amplitude of motion about the nominally measured value may not result in
clinically significant changes ~, a single fraction change in the prescription dose!, however, larger
variations ~.5 mm! can lead to significant changes. Assuming from measurement that the patient
breathes asymmetrically ~spends more time at expiration!, variations in the assumed degree of
asymmetry rarely lead to clinically significant changes; the most significant cause for concern being
when the patient breathing cycle is maximally different from the treatment planning case ~e.g.,
patient assumed to spend more time at expiration, but later breaths symmetrically!. The results point
out where quality assurance efforts should be concentrated to help assure the validity of the as-
sumptions used to correct the static dose distributions for patient breathing using the convolution
method. © 2003 American Association of Physicists in Medicine. @DOI: 10.1118/1.1609057#
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A method has previously been presented to incorporate rigid-
body organ motion due to breathing into three-dimensional
~3D! dose calculations for the treatment of liver disease.1
This method is based on the convolution of a static dose
distribution with a probability distribution function ~PDF!
that describes the organ motion due to breathing. Observa-
tions of the motion of the diaphragm ~and by inference the
liver! under fluoroscopy showed that organ motion due to
breathing is predominantly in the superior-inferior ~SI!
direction2–4 and is periodic but asymmetric with more time
spent near the position at expiration compared to the position
at inspiration. In an ultrasound study, Davies et al.3 report
that the motion of the liver is on average 2 mm less than the
motion of the diaphragm. Korin et al.4 found that the pre-
dominant motion of the liver was in the SI direction with
little expansion or contraction. In the previous study,1 the
effects of rigid-body organ motion due to breathing on the
treatment plan and prescription dose were retrospectively
analyzed in the context of a focal liver dose escalation treat-
ment protocol used at the University of Michigan ~UM!.5–7
Patients are CT scanned at the exhale position with asym-
metric planning target margins designed for each patient
based on the motion observed under fluoroscopy to account
for the patient free-breathing during treatment. In that proto-
col, the prescription ~protocol! dose is determined based8 on
the effective volume9,10 of the uninvolved liver. Rigid-body2643 Med. Phys. 30 10, October 2003 0094-2405Õ2003Õ30organ motion can be incorporated into the treatment planning
dose calculation to mimic potential changes to the dose dis-
tribution during treatment ~patient breathing freely!. The re-
sulting effective volume and hence prescription dose is then
determined. Nominal parameters describing the PDF used to
model the organ motion ~amplitude of motion and degree of
asymmetry! are determined from pre-treatment fluoroscopy.
The goal of this study is to evaluate the consequence of
errors in the selection of those parameters. Potential differ-
ences between the nominal parameters and the parameters
that may more truly describe the actual motion will be ana-
lyzed using the UM protocol for treatment of focal liver tu-
mors.
II. METHODS AND MATERIALS
The algorithm for convolving organ motion due to breath-
ing has previously been presented1 and is summarized as
D¯ ~x ,y ,z !5E D0~x ,y ,z2z8!pom~z8!dz8, ~1!
where D¯ (x ,y ,z)5dose to a point (x ,y ,z) incorporating the
effects of organ motion, D0(x ,y ,z2z8)5static treatment
dose calculation to a point (x ,y ,z2z8), and pom(z8)5PDF
that describes organ motion in the SI direction due to breath-
ing.
The PDF is based on a model describing organ motion
given by264310Õ2643Õ7Õ$20.00 © 2003 Am. Assoc. Phys. Med.
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where z(t)5position of organ at time t , z05position at ex-
piration, b5amplitude ~extent! of motion, z02b5position
at inspiration, t5period of motion, and n5degree of asym-
metry ~larger n5more time near expiration!. The corre-
sponding PDF is given as
pom~z !5H nbpS z02zb D (2n21)/2n
3F12S z02zb D
1/nG1/2J 21 for z02b,z,z0 . ~3!
This PDF depends solely on the amplitude of motion and
degree of asymmetry. Use of this single PDF in Eq. ~1! as-
sumes that patient breathing does not vary over the course of
treatment. In reality, the amplitude of patient breathing may
vary over time or the patient may occasionally take deep
breaths during the course of treatment. Such variations may
compromise the selection of a single amplitude for the mo-
tion and/or a single degree of asymmetry for the breathing
pattern.
As can be seen in Fig. 1, more than one value of n may
seem appropriate for a single observation of the breathing
pattern (n is restricted to integer values!. Alternatively, a
patient may breathe in a quite different manner during treat-
ment compared to the manner observed under treatment
planning conditions. However in practice, a nominal param-
eter set ~amplitude of motion and degree of asymmetry! is
usually selected for a patient simulation to predict the effects
of the organ motion due to breathing over the projected
course of treatment.
Here, the computationally fast convolution method ~using
the initial-nominal breathing parameters! is compared to di-
rect simulations1,11,12 of expected patient outcomes ~allowing
for deviations and/or variations from the initial parameter
set! to identify the sensitivity of the single observation con-
volution method to changes in the breathing parameters. This
direct simulation method is summarized in the following.
~1! The organ displacement ~away from the nominal expira-
tion position! due to breathing as a function of time was
separated into 10 discrete evenly spaced ~in distance!
bins. The time-weighted average organ position in each
bin was computed using the amplitude b , and degree of
asymmetry n specified for any particular simulation.
~2! The change in organ position was simulated in the treat-
ment planning system by moving the beams and iso-
center in a direction opposite to the motion.
~3! Monitor units were held constant to compute dose at
other positions in the respiratory cycle.
~4! The dose distribution was recalculated for each position
simulated.
~5! The probability pbi of finding the organ in the ith bin
based on the motion described with Eq. ~2! was com-
puted.
~6! Each calculation was weighted by pbi .Medical Physics, Vol. 30, No. 10, October 2003~7! Individual simulations were summed to form a compos-
ite dose distribution using the original treatment plan-
ning geometry as a backdrop.
In this study, nominal values of b51.5 cm ~amplitude of
FIG. 1. Measured time course of breathing for a sample patient based on
diaphragm motion ~away from the expiration position! as observed under
fluoroscopy compared to model given by Eq. ~2! using ~a! n53, ~b! n52,
and ~c! n56.
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based on general observations of diaphragmatic movement
under fluoroscopy for many patients.
A. Variations in the amplitude of motion
For a fixed degree of asymmetry (n53), the amplitude of
motion was varied from b51.2 cm to b51.8 cm ~in 0.1 cm
increments! and the probability per bin, pbi(b ,n53) was
calculated. Direct simulations of the organ motion for each b
~assumed to remain constant over the course of treatment!
were performed as described earlier. Deep-breath conditions
were also simulated for b52.0, 2.5, and 3.0 cm. Two occa-
sional deep-breath scenarios were calculated to simulate the
effect of a patient breathing normally (b51.5 cm) for 75%
of the treatment while taking a deep breath (b53.0 cm) 25%
of the time ~henceforth referred to as db1!, and a simulation
was performed to show the effects of a patient taking a deep
breath (b53.0 cm) only 10% of the treatment time and
breathing normally for the remainder of the treatment ~re-
ferred to as db2!.
Next, a treatment was simulated for b51.2 cm 50% of the
time, and b51.8 cm 50% of the time ~referred to as avg 1!.
For each of the above-mentioned simulations, values for
pbi(b ,n53) were calculated and the dose distributions were
re-calculated using our direct simulation.
B. Variations in the asymmetry of the breathing cycle
For a fixed value of b51.5 cm, the degree of asymmetry
was varied from n51 ~symmetric periodic function! to n
510 ~highly asymmetric with approximately 70% of the
time spent near the expiration position! (n53 is the nominal
value!. We also performed simulations for n50 ~patient near
the inspiration position for the entire treatment!, n550 ~ap-
proximately 86% of the time spent near the expiration posi-
tion!, and n5100 ~approximately 90% of the time spent near
the expiration position!. For each n , pbi(n ,b51.5 cm) was
calculated and the corresponding dose distribution computed
using our direct simulation procedure.
C. Clinical assessment of dose distribution
simulations
For each dose distribution calculated, the effective vol-
ume of the uninvolved liver ~liver minus gross tumor vol-
ume! was computed and the corresponding prescription dose
~assigned by the physician based on the protocol! was deter-
mined based upon iso-complication probability curve ~10%
risk of complication! for the liver as shown in Fig. 2.6 The
prescription dose is incremented in 1.5 Gy steps and rounded
to the lower 1.5 gray fraction with a maximum prescription
dose of 90 Gy, and a minimum dose of 36 Gy ~corresponding
to a Veff of 0.90%! depending on the risk level.
D. Patient analysis
Ten patient geometries were simulated as described earlier
for this study. All patients were treated on clinical trials6,7
after informed consent was obtained in accordance with the
procedures of the Institutional Review Board ~IRB! of theMedical Physics, Vol. 30, No. 10, October 2003University of Michigan, and CT-scanned for treatment plan-
ning with voluntary breath-hold at normal expiration.2 Tu-
mor volumes were located in the upper ~superior! portion of
the liver ~5 patients! or in the inferior portion of the liver ~5
patients!. Planning target volume ~PTV! margins were origi-
nally designed individually for each patient using their mea-
sured breathing excursion inferiorily.2 However, to normalize
the results of the simulations here, we assumed each patient’s
nominal treatment plan included a standard 15 mm of excur-
sion for breathing (b51.5 cm). The nominal prescription
dose ~again, as assigned by the physician based on the pro-
tocol! was determined for each patient based on this nominal
15 mm excursion for breathing. All patients were planned
using our in-house treatment planning software ~UMPLAN—
University of Michigan, Ann Arbor!.
III. RESULTS
Table I summarizes the changes in effective volume due
to variations in the amplitude of motion (b), deep breath
scenarios ~db 1 and db 2!, the average simulation ~avg 1! as
well as changes in asymmetry (n) described earlier for rep-
resentative patients with tumors located in the superior (Ia)
and inferior (Ib) portions of the liver, respectively. The
nominal simulation values (n53, b51.5 cm) are indicated
as are the values for the static (b50) treatment plan ~no
accounting for dose changes due to breathing!.
For each patient studied, there is a change in the effective
volume of the uninvolved liver when the effects of organ
motion due to breathing are included in the dose calculation.
In all cases ~CT scan performed at expiration! regions supe-
rior to the tumor volume move into the beam and regions
inferior to the tumor move out of the beam as the patient
breathes. For patients 1–5 with tumors located in the supe-
rior portion of the liver, organ motion due to breathing re-
sults in a decrease in the effective volume compared to the
static (b50) situation. For patients with tumors in the infe-
rior portion of the liver, the effective volume will increase as
the patient breathes. These changes in Veff determined prior
to treatment may have resulted in the physician making
changes to the prescription dose if they had known this prior
to treatment.13 For treatment geometries in which the tumor
is located in the middle portion of the liver ~simulations not
included here!, the overall volume of the liver that is exposed
FIG. 2. Iso-complication probability curve for the liver for 10% risk level as
a function of prescription dose ~Ref. 8!.
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little, although some change is expected due to the asymmet-
ric shape of the liver itself.
A. Variations in the amplitude of motion
As the amplitude ~extent! of motion varies in a narrow
range (b51.2 to b51.8 cm) about the nominal (b51.5)
value, the effective volume of the normal liver only changes
slightly ~middle portion of Fig. 3!. However, in all cases the
magnitude of the variation is less than the original change
from the static (b50) case obtained by accounting for the
average motion in the first place.
For all the patients severe over-estimation of the ampli-
tude at planning (b→0 relative to the assumed b51.5 cm)
leads to large changes in Veff ~far left portion of Fig. 3!. For
larger under-estimations of the amplitude at planning (b
52.0 to b53.0 cm relative to the assumed b51.5 cm), the
change in Veff relative to the nominal value will increase for
tumors located in the superior portion of the liver ~far right
portion of Fig. 3!. These variations in Veff about the nominal
TABLE I. Effective volume of the uninvolved liver for two representative
patients; one with a tumor located in the superior (Ia) portion of the liver
and one with a tumor located in the inferior (Ib) portions of the liver. Veff as
a function of b for a fixed degree of asymmetry (n53) and Veff as a
function of n for a fixed amplitude of motion (b51.5 cm) are shown. Nomi-
nal values (b51.5 cm, n53) are indicated. Key: db15simulation of pa-
tient breathing with nominal amplitude 75% of time, and deep breath (b
53.0 cm) 25% of the time, db25simulation of patient breathing with nomi-
nal amplitude 90% of the time and deep breath 10% of the time, avg1
5simulation of patient breathing with b51.2 cm 50% of the time, and b
51.8 cm 50% of the time.
b ~cm! Veff ~%! n Veff ~%!
~a! 0.0 37.92 0 26.77
1.2 34.91 1 31.90
1.3 34.69 2 33.27
1.4 34.36 3 34.07
1.5 34.07 4 34.53
1.6 33.80 5 34.80
1.7 33.49 6 35.00
1.8 33.20 7 35.23
2.0 32.63 8 35.39
2.5 31.17 9 35.57
3.0 29.69 10 35.58
db 1 32.95 ‘ 37.92
db 2 33.62
avg 1 34.05
~b! 0.0 38.26 0 49.09
1.2 40.99 1 43.43
1.3 41.09 2 41.88
1.4 41.22 3 41.32
1.5 41.32 4 40.90
1.6 41.44 5 40.57
1.7 41.53 6 40.30
1.8 41.60 7 40.21
2.0 41.70 8 40.08
2.5 41.81 9 40.04
3.0 41.63 10 39.84
db 1 41.30 ‘ 38.26
db 2 41.30
avg 1 41.26Medical Physics, Vol. 30, No. 10, October 2003value can also lead to changes in the prescription dose in our
protocol setting.
The above-mentioned results assume that the patient
breathes with the same ~but different from that originally
planned! magnitude throughout the entire course of treat-
ment, and represent potential worst-case scenarios. If the am-
plitude of breathing varies over the course of treatment, a
situation such as that presented in avg 1 may result ~50% of
the treatment spent at extremes about the nominal position,
b51.2 and b51.8 cm). The value of Veff will change from
the nominal value ~Table I!, but the change may not be suf-
ficient to warrant a change from the nominal prescription
dose.
In situations where the patient occasionally takes deep
breaths over the course of treatment ~db 1, db 2!, the effec-
tive volume also changes from the nominal value ~Table I!.
However, if a patient takes a deep breath even 25% of the
time during the course of treatment, there will likely only be
a single fraction change in the protocol dose ~db 1! and for a
10% deep breath simulation ~db 2!, potentially no change in
the prescription dose.
B. Variations in the asymmetry of the breathing cycle
The results of the studies of variations in the asymmetry n
are also summarized in Table I and Fig. 4, where n5‘ rep-
resents the static treatment plan ~no motion!. As the degree
of asymmetry increases (n increases!, the amount of time a
patient spends near the expiration position will increase, and
as would be expected, the effective volume of the uninvolved
liver approaches the value of Veff for the static (b50) treat-
ment plan that did not account for motion ~again, patients
were scanned near the expiration position!. This asymptotic
trend is observed by n510 as seen in Fig. 4 hence, the data
for n550, n5100 are not shown. For n50 ~patient treated
near the inspiration position!, there is a large difference be-
tween the effective volume predicted using our nominal
value n53 and the effective volume resulting from n50 ~far
left portion of Fig. 4!. This is consistent with the patient
treatment position being maximally different from both the
FIG. 3. Change in Veff from the nominal value computed for b51.5 cm and
n53 as a function of b . Solid line and open circles represent patients 1–5
~tumors in the superior portion of the liver!, dashed line and closed circles
represent data for patients 6–10 ~tumors in the inferior portion of the liver!.
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situation in which the patient breathes freely. In all other
cases, the largest remaining difference in Veff ~relative to the
nominal case! is for the patient breathing in a completely
symmetric pattern (n51) when an asymmetric breathing
pattern (n53) had been assumed. The resultant changes in
the effective volume are, in many cases, sufficient to justify a
change in the protocol dose to maintain a fixed risk of com-
plication. The effective volumes change in manners consis-
tent with the above-noted observations for the superior and
inferior tumor geometries.
IV. DISCUSSION
Intra-treatment organ motion due to breathing can lead to
erroneous prediction of the dose delivered to a patient when
a computed tomography ~CT! scan of a patient is used for
treatment planning dose calculations ~even in cases where
the CT is obtained with a patient breath-hold at inspiration or
expiration! if treatment is not also delivered accordingly.
Previously, we proposed a simple model to describe the or-
gan motion due to breathing that depends upon specification
of the extent of motion b , and the asymmetry of the breath-
ing cycle n ~parameters are selected from pre-treatment fluo-
roscopy!. Here, we have investigated the effects that poten-
tial errors in the selection of these parameters may have on
the resultant dose distribution by examining variations in the
parameters about nominal values.
As the amplitude ~extent! of motion varies about the
nominally observed value, Veff will also vary ~which may, in
turn, effect the selection of the prescription dose in our pro-
tocol!. The magnitude of the change in Veff required to affect
a change in the protocol dose ~relative to the prescription
dose in the nominal setting! is a function of the nominal
value of Veff .
It is possible to estimate the magnitude of change in Veff
that would be sufficient to result in a change in the prescrip-
tion dose. The scale of the prescription dose is divided into
evenly spaced dose bins of 1.5 cm. If we examine the iso-
FIG. 4. Change in Veff from the nominal value computed for b51.5 cm and
n53 as a function of n . Solid line and open circles represent patients 1–5
~tumors in the superior portion of the liver!, dashed line and closed circles
represent data for patients 6–10 ~tumors in the inferior portion of the liver!.
Data at n510 begin to demonstrate asymptotic approach to n5‘ value.Medical Physics, Vol. 30, No. 10, October 2003NTCP curve ~Fig. 2! used to determine the prescription dose
~based on Veff), we see that for small values of Veff ~,0.40!,
approximately a 2.5% change in the effective volume will
result in a single fraction ~1.5 Gy! change in the prescription
dose. For medium and high Veff values ~.0.40!, changes in
the prescription dose ~in 1.5 Gy steps! are associated with
3%–6% changes in Veff . The percent change in Veff ~relative
to the nominal value! is shown in Fig. 3 for changes in the
extent of motion from b50 cm to b53.0 cm relative to the
nominal b51.5 cm case.
If we examine small (b51.2 cm to b51.8 cm) variations
about the nominal value ~changes that might be associated
with systematic error in the original measurement of ampli-
tude!, we see that the percent change in Veff is small ~less
than 3%! compared to the original change in Veff from the
static treatment case (b50 cm). These variations are gener-
ally larger for tumors located in the superior portion of the
liver. However, the magnitude of these changes is, in most
cases, only sufficient to warrant at most a single fraction ~1.5
Gy! change in the prescription dose from the nominal value.
Similar changes in Veff are seen for our average simulation
avg 1 in Table I.
Again, specific results will depend upon the exact treat-
ment geometry as well as the PTV margins selected for the
treatment. While the relative change in Veff is small for small
variations in the amplitude of motion about our nominal
value, the change in Veff is potentially large ~up to 15%! for
large changes (b50, or b52.0 to b53.0 cm). These larger
changes may result in more than a single fraction change in
the prescription dose. These deep-breath (b52.0 to b
53.0 cm) or no-breath (b50) simulations assume that the
patient would breathe with fixed, but incorrect ~relative to
the nominal parameters selected during treatment planning!,
amplitude over the entire course of treatment. In an actual
treatment, it is more realistic to assume that the average am-
plitude of the patient’s breathing is relatively constant ~e.g.,
b51.5 cm) but the patient may take occasional deep breaths
during the course of treatment. Our simulations ~Table I! of
these more realistic situations ~db 1 and db 2! show that if a
patient takes a deep breath for even up to 25% of the treat-
ment, the change in Veff ~relative to the nominal value! is
only sufficient to warrant at most a single fraction change in
the prescription dose. If the patient should breathe deeply for
only 10% of the treatment, the change in Veff may be insuf-
ficient to warrant any additional change in the prescription
dose ~from the nominal value!.
The asymmetry of a patient’s breathing cycle may also
vary over the course of treatment, and the magnitude of this
variation is worth considering in the context of our model.
The motion of a patient’s diaphragm ~as observed under fluo-
roscopy! is shown in Fig. 1 along with our mathematic
model. Figure 1~a! shows the same measured data along with
our model using n53, while Fig. 1~b! shows the measured
data with our model using n52. If we compare this to Fig.
1~c!, which shows the measured patient data along with our
model using n56, we see that it is reasonable to assume that
any of these values of n would be sufficient to adequately
describe the time course of breathing ~recall, our choice of n
2648 Lujan, Balter, and Ten Haken: Organ motion due to breathing: Sensitivity to variations 2648is limited to integer values!. These observations highlight the
importance of observing a patient breathe over many cycles
to provide enough data to simplify our choice of both n and
b .
The percent change in Veff as a function of n ~relative to
the nominal value of n53) is shown in Fig. 4. From the
data, it is clear that the largest change in Veff occurs for n
50. This is entirely consistent, as for the n50 scenario the
treatment takes place with the patient near the inspiration
position in the breathing cycle 100% of the time, a situation
completely counter to the treatment planning ~scan at expi-
ration! situation. As the degree of asymmetry increases from
the assumed value, the value of Veff begins to slowly ap-
proach the static ~expiration! simulation geometry (n5‘).
Assuming that the patient breathes freely over the course
of treatment, the largest remaining differences are for simu-
lations where the patient breathes symmetrically n51 when
an asymmetric breathing pattern (n53) had been assumed.
These changes in Veff could be large enough to cause a one
or more fraction change in the prescription dose. However,
for an asymmetric breathing cycle, our results indicate that
our model is relatively insensitive to small changes in the
degree of asymmetry. Further, these small changes in the
asymmetry would be generally insufficient to result in varia-
tions in Veff large enough to change the prescription dose.
If we are interested in predicting the dose delivered dur-
ing the course of treatment, careful observations of the nature
of organ motion will be required. For example, our results
indicate that our prediction of Veff is sensitive to the ampli-
tude of motion b that we select to model the patient’s breath-
ing cycle. Therefore, for an accurate prediction of the dose
distribution, it is important to observe and sample the ampli-
tude of the breathing cycle for each patient to determine a
proper magnitude for the parameter b . Further, if in our ob-
servations, we find that the extent of motion for a patient
varies greatly, additional efforts may be required to control
or monitor the patient’s breathing cycle.14 –18 However, if the
amplitude of the breathing motion varies about some nomi-
nal value, it is likely that the prescription dose will not
change from that selected using that nominal value of b
~note: in Fig. 3 the value of Veff changes sign about the
nominal value for positive or negative changes; thus varia-
tions that might be associated with random changes in the
breathing amplitude would by and large cancel out!.
Similarly, we must also be aware of the degree of asym-
metry in a patient’s breathing cycle for an accurate prediction
of the dose distribution. Though our predictions of Veff are
less sensitive to minor changes in the degree of asymmetry
for n.2, there is a larger change between a purely symmet-
ric breathing cycle (n51) and a breathing cycle that in-
cludes any degree of asymmetry. Hence, if we begin to use
methods that cause a patient to breathe in a symmetric pat-
tern, our values selected for n must reflect this change as
well. As expected, the worst possible scenario is one in
which patients do not breathe freely during the treatment but
instead hold their breath near positions far away from where
they were treatment planned ~e.g., scanned at expiration, but
treated at inspiration!. In those cases, the effective volumeMedical Physics, Vol. 30, No. 10, October 2003calculated for the static geometry or for free breathing simu-
lations will greatly differ from the actual dose delivered ~up
to 25% differences in Veff values between n50 and n53).
Again, in such cases, special techniques may be required.
Finally, as the nature of the organ motion is better under-
stood and parametrized, confirmation of convolution-based
procedures to simplify the analysis of organ motion due to
breathing will require direct simulations that include the ef-
fects of changes in the patient external contour, any organ
motion that may be present, organ deformation,19 and any
inhomogeneity corrections that may be required.19,20 In ad-
dition, a more complex PDF may be required to model the
more complex motion. We have presented here a basic
framework to verify convolution-based studies.
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